On a mission to simplify cell therapy manufacturing and bring life-saving treatments closer to patients.

For years, the promise of personalized cell therapy has been overshadowed by one critical hurdle, manufacturing. The process, often manual and resource-intensive, makes it difficult to scale treatments efficiently. Patients in urgent need are left waiting, and companies face rising costs with limited capacity. The industry needed more than innovation in treatment, it needed transformation in how these therapies are made.

Adva Biotechnology Ltd, under the leadership of Dr. Ohad Karnieli, has taken on this challenge with a clear vision. With years of experience in the field of cell and gene therapy, he understood that solving the manufacturing issue was just as important as developing the therapy itself.

Adva’s solution is the ADVA X3, an advanced, all-in-one system designed to make the manufacturing process simpler, faster, and more reliable. This closed and automated platform can carry out complex steps without the need for large cleanrooms or constant manual handling. It uses real-time monitoring and intelligent technology to ensure quality at every stage. It is also...